ERBB2 and breast carcinoma: Conjugation of trastuzumab to MCPs presenting 24–29 DTPA chelators increased the SA of trastuzumab labelled with 111In by 90-fold compared to trastuzumab conjugated to DTPA and increased the cytotoxicity of these RICs in vitro on HER2-positive breast cancer (BC) cells, including cells with low-moderate HER2 expression (Ngo Ndjock Mbong et al. 2015).